Studies show that financial incentives for low-risk clinical trials are ethical

JAMA Internal MedicineHe was a co-author of a study published in. Credit: Northwestern University “width =” 480 “height =” 530 “/>

Dr. Brian Hitsman is an Associate Professor of Preventive Medicine in the Departments of Behavioral Medicine, Medical Social Sciences, Psychiatry and Behavioral Sciences. JAMA Internal Medicine..Credit: Northwestern University

The use of financial incentives in two low-risk randomized clinical trials did not pose an ethical question, and in one of the trials, the incentive increased participation in the study. JAMA Internal Medicine..

Results can help address low or inadequate long-standing problems register In clinical practice trial In many areas of medicine, Dr. Brian Hitsman, an associate professor of preventive medicine in the Department of Behavioral Medicine and co-author of the study, said.

“Hopefully our results will encourage people to be open to the idea of ‚Äč‚Äčincreasing registration to. Low risk “Clinical trials with financial incentives for participants,” said Hitsman, an associate professor of medicine and social sciences and psychiatry and behavioral sciences.

One of the biggest barriers to accurate and efficient randomized clinical trials is the difficulty of enrolling participants. Historically, researchers have sought to increase research enrollment through several strategies, including providing financial incentives to research participants. However, it has not yet been studied whether this practice actually increases participation.

Moreover, according to the author, practice ethics has long been an unanswered question. Two of the most common concerns among researchers encouraging research participation are that incentives can represent excessive incentives. That is, it dismisses or downplays the risks associated with study participation, thereby interfering with complete informed consent or unjustified incentives and encouraging the enrollment of low-income people. Otherwise, he would not have participated in the study.

In the current study, a total of 1,296 eligible participants were enrolled in two randomized clinical trials with incentives. One compared smoking cessation interventions and the other evaluated gait (walking) interventions. Hitsman was a senior researcher in the clinical setting of smoking trials at Northwestern University.

50% of the participants in the smoking test were women. Average age 50 years. 60% were identified as Black or African American, 32.7% were Caucasian, and 3.7% were multi-ethnic. 57% of the participants in the gait test were women. Average age 47 years. 35% are black or African American, 52% are white, and less than 1% are multi-ethnic.

Participants then randomly receive a $ 0, $ 200, or $ 500 financial incentive to participate in the smoking test and a $ 0, $ 100, or $ 300 financial incentive to participate in the walking test. Assigned.

The conclusions of both trials revealed that financial incentives increased enrollment in smoking cessation trials, but not gait trials. Non-inferiority tests conducted by researchers also disproportionately incentives to participants who reported lower income levels to enroll (unjustified incentives) or lower perceptual risk to participate in the trial (non-incentives). I found that I wasn’t motivated.

“One of the potential explanations for the different results is that the gait test provided a lower-risk intervention than the smoking cessation test,” said Hitsman, a member of the Robert H. Lully Cancer Center at Northwestern University. “.

The results show that providing financial incentives for research participation is not unethical, Financial incentives According to the author, what was offered for high-risk clinical trials needs further investigation.

“Two” parents ” Clinical trials Limitations that differed in terms of true risk smoking The discontinuation study found that both trials were testing low-risk interventions. The impact of registration incentives on candidates considering high-risk medical interventions, including: Cancer treatment, It can be different, so we need to consider this next, “Hitzman said.

Studies have found that people with color are more likely to participate in cancer clinical trials

For more information:
Scott D. Halpan et al., Effectiveness and ethics of incentives for research participation, JAMA Internal Medicine (2021). DOI: 10.1001 / jamainternmed.2021.5450

Quote: According to research, financial incentives for low-risk clinical trials are ethical (October 26, 2021) and on October 26, 2021 Obtained from -incentives-low-risk-clinical-trials. html

This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.

Studies show that financial incentives for low-risk clinical trials are ethical

Source link Studies show that financial incentives for low-risk clinical trials are ethical

Show More

Related Articles

Back to top button